Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6NCya-Olfml2aem1/Cya
Common Name:
Olfml2a-KO
Product ID:
S-KO-07294
Background:
C57BL/6NCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Olfml2a-KO
Strain ID
KOCMP-241327-Olfml2a-B6N-VA
Gene Name
Olfml2a
Product ID
S-KO-07294
Gene Alias
4932431K08Rik; mFLJ00237
Background
C57BL/6NCya
NCBI ID
241327
Modification
Conventional knockout
Chromosome
2
Phenotype
MGI:2444741
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6NCya-Olfml2aem1/Cya mice (Catalog S-KO-07294) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000057279
NCBI RefSeq
NM_172854
Target Region
Exon 3~7
Size of Effective Region
~11.7 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Olfml2a, belonging to the olfactomedin domain-containing secreted glycoprotein family, is expressed in various tissues such as the retina [5,6]. Its function might be related to the development and functional organization of the nervous system and retina, and it is evolutionarily conserved under purifying selection [5,6].

In cancer research, high OLFML2A expression is associated with an unfavorable prognosis in patients with AML. It can act as a molecular indicator involved in the diagnosis, prognosis, and immune process of AML, potentially improving the molecular biology prognostic system and treatment selection for AML [1]. In glioma, OLFML2A expression is upregulated, positively correlated with pathological grades, and patients with higher expression have shorter overall survival. Knockdown of OLFML2A in glioma cells inhibits cell proliferation, promotes apoptosis, and suppresses the growth of transplanted glioma by inhibiting the Wnt/β-catenin signaling pathway [2]. In triple-negative breast cancer (TNBC), high OLFML2A level is associated with poor prognosis. OLFML2A is a key regulatory protein acting downstream of AP-1 and is necessary for the anti-TNBC effect of the selective activator protein-1 inhibitor T-5224. Silencing OLFML2A in TNBC cells inhibits proliferation, migration, and invasion, and promotes apoptosis by inducing S phase arrest and decreasing epithelial-mesenchymal transition [3,4].

In conclusion, Olfml2a plays significant roles in the development of certain tissues like the retina. In diseases, especially in cancers such as AML, glioma, and TNBC, Olfml2a is closely related to disease prognosis and progression. Its study in these disease models helps understand the underlying molecular mechanisms, providing potential therapeutic targets and prognostic markers.

References:

1. Lu, Xuan, Li, Ying, Yang, Yan, Chai, Xingxing, Gong, Chen. 2023. OLFML2A Overexpression Predicts an Unfavorable Prognosis in Patients with AML. In Journal of oncology, 2023, 6017852. doi:10.1155/2023/6017852. https://pubmed.ncbi.nlm.nih.gov/36873740/

2. Ma, Shize, Duan, Lei, Dong, Huateng, Pan, Yawen, Zhang, Yinian. 2021. OLFML2A Downregulation Inhibits Glioma Proliferation Through Suppression of Wnt/β-Catenin Signaling. In Frontiers in oncology, 11, 717917. doi:10.3389/fonc.2021.717917. https://pubmed.ncbi.nlm.nih.gov/34650914/

3. Zhao, Qian, Zhang, Kaixin, Li, Yong, Qiao, Yichun, Liu, Yawen. 2021. OLFML2A is necessary for anti-triple negative breast cancer effect of selective activator protein-1 inhibitor T-5224. In Translational oncology, 14, 101100. doi:10.1016/j.tranon.2021.101100. https://pubmed.ncbi.nlm.nih.gov/33993098/

4. Gao, Xiufei, Yang, Zimei, Xu, Chuchu, Wu, Chunyu, Chen, Mingcang. . GeneChip expression profiling identified OLFML2A as a potential therapeutic target in TNBC cells. In Annals of translational medicine, 10, 274. doi:10.21037/atm-22-757. https://pubmed.ncbi.nlm.nih.gov/35433966/

5. Garza-Rodríguez, María Lourdes, González-Álvarez, Rafael, Mendoza Alfaro, Roberto Eduardo, Aguilera González, Carlos Javier, Rodriguez Sanchez, Iram Pablo. 2019. Olfactomedin-like 2 A and B (OLFML2A and OLFML2B) profile expression in the retina of spotted gar (Lepisosteus oculatus) and bioinformatics mining. In Fish physiology and biochemistry, 45, 1575-1587. doi:10.1007/s10695-019-00647-0. https://pubmed.ncbi.nlm.nih.gov/31111317/

6. Pérez-Ibave, Diana Cristina, González-Alvarez, Rafael, de La Luz Martinez-Fierro, Margarita, Barrera-Saldaña, Hugo Alberto, Rodríguez-Sánchez, Irám Pablo. 2016. Olfactomedin-like 2 A and B (OLFML2A and OLFML2B) expression profile in primates (human and baboon). In Biological research, 49, 44. doi:. https://pubmed.ncbi.nlm.nih.gov/27821182/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest